In Sweden, people vaccinated against COVID-19 before a SARS-CoV-2 infection had a lower risk of developing post-COVID-19 condition (PCC; “long COVID”), according to a register-based
In the ACTIV-6 trial, fluvoxamine was not effective in reducing the duration of mild-to-moderate COVID-19 among ambulatory patients. “Although one-third fewer health care use events
Coadministration of the BNT162b2 BA.4/5 bivalent mRNA COVID-19 vaccine (BNT162b2-biv) and seasonal influenza vaccine (SIV) in the community setting produced similar effectiveness and outcomes as when
Of people treated for acute COVID-19 with nirmatrelvir–ritonavir (N-R), 20% experienced virologic rebound (VR), according to a Boston-area multicenter health system study. Many patients with
Two studies examine parental trust in vaccine information and polarization of attitudes during the COVID-19 pandemic and identify a number of vaccine concerns that can
Patients hospitalized with COVID-19 at 130 sites on 4 continents received little benefit from intravenous vitamin C, researchers report. The authors concluded that the intervention
In a retrospective target trial emulation study of U.S. veterans following acute COVID-19, ritonavir-boosted nirmatrelvir reduced the frequency of just 1 of 31 potential post–COVID-19
In a cohort study, unvaccinated people with COVID-19 had a 62% higher chance of developing new-onset diabetes mellitus (DM), while vaccinated individuals with breakthrough COVID-19
In a study of patients with the rare multisystem disease lymphangioleiomyomatosis (LAM), responses to COVID-19 mRNA vaccines were similar with and without sirolimus treatment, letter
Compared with placebo in ambulatory patients with confirmed COVID-19 who were aged 30 years or older, inhaled fluticasone furoate for 14 days did not shorten
